CGON 8-K: Fda approval
CG Oncology
Filed with the SEC on · accession 0001193125-26-462199
CGON filed a 8-K (current report) with the SEC on Nov 16, 2026. CG Oncology announced positive topline results from its Phase 3 PIVOT-006 registrational trial of adjuvant intravesical cretostimogene in intermediate-risk and high-grade Ta NMIBC, achieving its primary endpoint with a 68% reduction in recurrence risk (HR 0.32, p<0.0001).
Summary of the filing
CG Oncology announced positive topline results from its Phase 3 PIVOT-006 registrational trial of adjuvant intravesical cretostimogene in intermediate-risk and high-grade Ta NMIBC, achieving its primary endpoint with a 68% reduction in recurrence risk (HR 0.32, p<0.0001). The company also updated its BLA submission timelines, with the BCG-unresponsive NMIBC BLA now expected in March 2027 and a second BLA for intermediate-risk/high-grade Ta NMIBC planned for Q2 2027.
Key details
✦ Ask GOAX AI about this filing — what it means for CGON, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for CGON?
Click hereFrequently asked questions
What did CGON file with the SEC on Nov 16, 2026?
CGON filed a 8-K (Fda approval). CG Oncology announced positive topline results from its Phase 3 PIVOT-006 registrational trial of adjuvant intravesical cretostimogene in intermediate-risk and high-grade Ta NMIBC, achieving its primary endpoint with a 68% reduction in recurrence risk (HR 0.32, p<0.0001). The company also updated its BLA submission timelines, with the BCG-unresponsive NMIBC BLA now expected in March 2027 and a second BLA for intermediate-risk/high-grade Ta NMIBC planned for Q2 2027.
What does a fda approval mean for CGON stock?
For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other CGON SEC filings
- 8-K · SEC filingNov 6, 2026
- 10-Q · SEC filingNov 6, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
- SCHEDULE 13G/A · SEC filingAug 13, 2026
- 8-K · Secondary offeringAug 6, 2026
- 424B5 · Secondary offeringAug 6, 2026
- 10-Q · SEC filingAug 6, 2026
- 144 · Insider sale plannedJul 10, 2026
- 8-K · Board changeJun 8, 2026
Get alerts when CGON files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days